Opsumit as a Treatment for Children with PAH is Being Evaluated By Actelion

by Marta Ribeiro | July 9, 2016

Pulmonary hypertension (PH) is a serious heart and lung condition that can affect anyone, even children. There is still no known cure available and only a few treatment options that can be used to ease the symptoms for adults and none for children.

But researchers and drug companies have been working endlessly in an attempt to discover new treatment options, especially targeting children with pulmonary hypertension children.

Actelion will soon start a Phase 3 clinical trial to assess the effectiveness of Opsumit (macitentan) in delaying the progression of pulmonary arterial hypertension (PAH) in children and adolescents. The long-term trial, called TOMORROW (pediaTric use Of Macitentan tO delay disease pRogRessiOn in PAH Worldwide), will be conducted in more than 20 countries and may lead to the first approved treatment for young PAH patients.

But how will TOMORROW benefit children with PH? Find out more about it here.

Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Print This Page

About the Author

Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.